Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of “Moderate Buy” from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $12.00.

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $9.97 on Friday. Amneal Pharmaceuticals has a 1-year low of $6.68 and a 1-year high of $10.68. The stock has a market cap of $3.13 billion, a PE ratio of 998.00 and a beta of 1.18. The firm has a fifty day moving average price of $9.58 and a 200 day moving average price of $8.37.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Monday, July 21st. The company reported $0.21 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. The company had revenue of $695.42 million during the quarter. Amneal Pharmaceuticals has set its Q2 2025 guidance at EPS. As a group, equities analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total value of $1,105,992.72. Following the transaction, the executive vice president directly owned 152,743 shares in the company, valued at approximately $1,475,497.38. The trade was a 42.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the transaction, the executive vice president owned 152,426 shares in the company, valued at approximately $1,429,755.88. This represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 609,206 shares of company stock valued at $5,700,625. Company insiders own 26.56% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AMRX. Nuveen LLC acquired a new position in Amneal Pharmaceuticals in the first quarter valued at $19,581,000. Assenagon Asset Management S.A. increased its stake in Amneal Pharmaceuticals by 187.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,150,041 shares of the company’s stock valued at $21,522,000 after purchasing an additional 1,401,190 shares during the period. Rubric Capital Management LP increased its stake in Amneal Pharmaceuticals by 9.1% in the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock valued at $94,737,000 after purchasing an additional 974,355 shares during the period. Woodline Partners LP increased its stake in Amneal Pharmaceuticals by 165.2% in the first quarter. Woodline Partners LP now owns 1,504,095 shares of the company’s stock valued at $12,604,000 after purchasing an additional 937,035 shares during the period. Finally, Vanguard Group Inc. increased its stake in Amneal Pharmaceuticals by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after purchasing an additional 920,758 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.